Tag Archives: Sanofi SA

Update: CDC data say docs still making billions from Pharma, med device companies; my personal take.

The News: It’s been a few years since the US government unveiled its Open Payments (OP) database, a collection of drug and device makers’ payments to healthcare providers. The data-collection… Read more »

Tesaro says it’s for sale, but who can afford it

The News: Just ahead of the year’s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The Wall Street… Read more »

Stock markets closed Friday prior to collapse of Trumpcare; health sector’s biggest winners & losers as of March 24, 2017

Republican bickering has led to the biggest rout yet for President Trump’s early administration. As I expected, the GOP plan to gut the Affordable Care Act collapsed Friday (March 24,… Read more »

After Trump’s charge of “getting away with murder,” J&J, other Pharmas scramble to tout price restraints; but who’s kidding whom?

Steve’s Take: I thought the pharma business, like any other, was built on the bedrock precept of: charge what the market will bear, until you’re forced to pull back the… Read more »

FTC opens antitrust investigation of Mylan’s EpiPen dominance; isn’t it high time we live up to Churchill’s rejoinder?

The News: Mylan on Monday (January 30, 2017) acknowledged that the US Federal Trade Commission asked the company “months ago” to provide information about the allergy therapy EpiPen (epinephrine) as… Read more »

J&J finally captures Actelion for $30 billion; deal looks good for both unless “what ifs” bite pharma giant’s shareholders

The News: It took months but Swiss biotech Actelion Ltd. (Allschwil) said on Thursday (January 26, 2017) it had agreed to be purchased by Johnson & Johnson (New Brunswick NJ) in a… Read more »

Mallinckrodt will pay $100 million to settle drug antitrust (price-gouging) charges; why competition, not fines, is the only antidote

The News: Irish drugmaker Mallinckrodt PLC (Dublin) and a US subsidiary will pay $100 million and agree to other conditions to settle government antitrust allegations they unlawfully prevented competition for… Read more »

Drugs that may shape 2017 and the trends molding new-drug discovery

Here’s a look at the drugs that may shape 2017, compliments of FirstWord Pharma. It’s a list of some of the products I agree are likely to dominate industry news… Read more »

Biotech predictions for 2017 return to positive fundamentals; 2016 meltdown still in rear-view mirror

The NASDAQ Biotech Index got hammered in 2016–-but mostly due to the market melting in January 2016. The Nasdaq Biotech Index collapsed 28% in the opening weeks of 2016 and… Read more »

Gilead loses record $2.5 billion patent verdict to Merck; so what’s a couple billion when you’ve got plenty more and need to grow–fast?

Gilead Sciences Inc. (Foster City CA) was told by a federal jury to pay $2.54 billion to Merck & Co. (Kenilworth NJ) for using a patented invention as the basis for its… Read more »